MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

about

MAP Kinase-Interacting Kinase 1 Promotes Proliferation and Invasion of Hepatocellular Carcinoma and Is an Unfavorable Prognostic Biomarker.Contributions of Thyroid Hormone to Cancer Metastasis

P2860

Q52632734-D6D7FB9C-1FF7-4060-A9E6-1FCEF55BED94 Q58717087-56F9EF22-262F-4FF7-98D3-BA555F1A3E67

P2860

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Item

http://www.wikidata.org/entity/Q47649072

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

@en

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

@nl

type

Item

label

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

@en

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

@nl

prefLabel

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

@en

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

@nl

P1476

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

@en

P2093

Agnieszka Dreas

http://www.w3.org/2001/XMLSchema#string

Aniela Golas

http://www.w3.org/2001/XMLSchema#string

Bonnie Huor

http://www.w3.org/2001/XMLSchema#string

Christophe Goncalves

http://www.w3.org/2001/XMLSchema#string

Eliza Żyłkiewicz

http://www.w3.org/2001/XMLSchema#string

Fabrice Journe

http://www.w3.org/2001/XMLSchema#string

Fan Huang

http://www.w3.org/2001/XMLSchema#string

Ghanem E Ghanem

http://www.w3.org/2001/XMLSchema#string

Jie Su

http://www.w3.org/2001/XMLSchema#string

Jose Torres

http://www.w3.org/2001/XMLSchema#string

P2860

MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates

Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

Regulation of translation initiation in eukaryotes: mechanisms and biological targets

ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers

A small molecule-kinase interaction map for clinical kinase inhibitors

Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues

P304

4179-4192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI91258

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Ivan Topisirovic

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29035277

http://www.w3.org/2001/XMLSchema#string

P932

5663367

http://www.w3.org/2001/XMLSchema#string

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

about

P2860

P2860

MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932